Table of Contents
Sesen Bio, a little biotech agency whose investigational most cancers procedure as soon as seemed poised for acceptance, said Wednesday that it experienced withdrawn its software to sector the drug in Europe.
The news follows the Foods and Drug Administration’s determination to reject Sesen’s drug, named Vicineum, on Aug. 13. Very last week, STAT noted that Sesen’s scientific demo in bladder most cancers was marked by hundreds of violations, investigator misconduct, and proof of serious toxicity the company did not publicly disclose, according to hundreds of pages of inner paperwork.
Unlock this posting by subscribing to STAT+ and get pleasure from your initial 30 times absolutely free!
GET Began
What is it?
STAT+ is STAT’s premium subscription provider for in-depth biotech, pharma, coverage, and lifestyle science protection and examination.
Our award-winning workforce addresses information on Wall Avenue, plan developments in Washington, early science breakthroughs and clinical trial outcomes, and well being treatment disruption in Silicon Valley and over and above.
What is actually bundled?
- Day-to-day reporting and analysis
- The most extensive sector coverage from a powerhouse crew of reporters
- Subscriber-only newsletters
- Each day newsletters to quick you on the most critical industry information of the working day
- STAT+ Conversations
- Weekly possibilities to have interaction with our reporters and major industry experts in live video discussions
- Exclusive industry events
- Premium entry to subscriber-only networking events all around the place
- The most effective reporters in the field
- The most reliable and perfectly-connected newsroom in the wellness treatment market
- And substantially much more
- Distinctive interviews with field leaders, profiles, and top quality applications, like our CRISPR Trackr.
